Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19500738 | 0.89 | CDK1 (0.49) | ALDH1A1LMNASMN1; SMN2CTSBTSHR | |
| SCHEMBL9609632 | 0.88 | ALDH1A1 (0.51) | KMT2AALDH1A1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL2573641 | 0.84 | CTSB (0.67) | KMT2AALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL15687836 | 0.84 | KMT2A (0.51) | KMT2AALDH1A1CYP2D6L3MBTL1HPGD | |
| SCHEMBL18331627 | 0.83 | MAPT (0.50) | KMT2AALDH1A1CYP2D6L3MBTL1HPGD | |
| SCHEMBL15688075 | 0.82 | LMNA (0.71) | KMT2AALDH1A1CYP2D6L3MBTL1HPGD | |
| SCHEMBL25246395 | 0.81 | ALDH1A1 (0.50) | KMT2AALDH1A1CYP2D6L3MBTL1HPGD | |
| SCHEMBL1420633 | 0.81 | NR1H2 (0.49) | KMT2AALDH1A1CYP2D6L3MBTL1HPGD | |
| SCHEMBL28027182 | 0.81 | ALDH1A1 (0.48) | KMT2AALDH1A1CYP2D6L3MBTL1HPGD | |
| SCHEMBL31202966 | 0.80 | LMNA (0.43) | KMT2AALDH1A1LMNASMN1; SMN2CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629168-B2 | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors | NOVARTIS AG (CH) | 2014-01-14 | — | — | US | disclosed |
| CN-101516860-B | Benzoxazoles and oxazolopyridines being useful as FANUS kinases inhibitors | NOVARTIS AG | 2012-06-27 | — | — | CN | disclosed |
| EP-2066647-B1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2011-11-09 | — | — | EP | disclosed |
| US-20100009978-A1 | Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors | NOVARTIS AG | 2010-01-14 | — | — | US | disclosed |
| CN-101516860-A | Benzoxazoles and oxazolopyridines being useful as FANUS kinases inhibitors | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-2066647-A1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | Novartis AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008031594-A1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009978-A1 | Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors | JAK2, JAK3, JAK1 | KMT2A 1585/4885ALDH1A1 1245/4885CYP2D6 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.